$58.23
0.22% yesterday
Nasdaq, Jul 14, 10:00 pm CET
ISIN
US09061G1013
Symbol
BMRN

Biomarin Pharmaceutical Stock price

$58.23
+1.99 3.54% 1M
-5.58 8.74% 6M
-7.50 11.41% YTD
-26.36 31.16% 1Y
-28.48 32.85% 3Y
-68.20 53.94% 5Y
-89.02 60.46% 10Y
+50.73 676.40% 20Y
Nasdaq, Closing price Mon, Jul 14 2025
+0.13 0.22%
ISIN
US09061G1013
Symbol
BMRN
Sector
Industry

Key metrics

Basic
Market capitalization
$11.2b
Enterprise Value
$10.5b
Net debt
positive
Cash
$1.3b
Shares outstanding
191.8m
Valuation (TTM | estimate)
P/E
21.9 | 16.5
P/S
3.8 | 3.5
EV/Sales
3.6 | 3.3
EV/FCF
16.9
P/B
1.9
Financial Health
Equity Ratio
81.0%
Return on Equity
7.5%
ROCE
10.9%
ROIC
10.0%
Debt/Equity
0.1
Financials (TTM | estimate)
Revenue
$3.0b | $3.2b
EBITDA
$745.8m | $916.7m
EBIT
$712.0m | $839.4m
Net Income
$523.9m | $675.1m
Free Cash Flow
$620.2m
Growth (TTM | estimate)
Revenue
19.4% | 12.3%
EBITDA
235.3% | 49.5%
EBIT
301.6% | 47.3%
Net Income
155.0% | 58.2%
Free Cash Flow
280.0%
Margin (TTM | estimate)
Gross
79.4%
EBITDA
25.3% | 28.6%
EBIT
24.1%
Net
17.8% | 21.1%
Free Cash Flow
21.0%
More
EPS
$2.7
FCF per Share
$3.2
Short interest
3.0%
Employees
3k
Rev per Employee
$940.0k
Show more

Is Biomarin Pharmaceutical a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,006 stocks worldwide.

Biomarin Pharmaceutical Stock Analysis

Unlock Scores for Free

Analyst Opinions

35 Analysts have issued a Biomarin Pharmaceutical forecast:

28x Buy
80%
7x Hold
20%

Analyst Opinions

35 Analysts have issued a Biomarin Pharmaceutical forecast:

Buy
80%
Hold
20%

Financial data from Biomarin Pharmaceutical

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
2,950 2,950
19% 19%
100%
- Direct Costs 607 607
18% 18%
21%
2,344 2,344
20% 20%
79%
- Selling and Administrative Expenses 897 897
5% 5%
30%
- Research and Development Expense 701 701
10% 10%
24%
746 746
235% 235%
25%
- Depreciation and Amortization 34 34
25% 25%
1%
EBIT (Operating Income) EBIT 712 712
302% 302%
24%
Net Profit 524 524
155% 155%
18%

In millions USD.

Don't miss a Thing! We will send you all news about Biomarin Pharmaceutical directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Biomarin Pharmaceutical Stock News

Neutral
PRNewsWire
14 days ago
SAN RAFAEL, Calif. , July 1, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) said today that it completed the previously announced agreement to acquire Inozyme Pharma, Inc. (Nasdaq: INZY) for $4.00 per share in an all-cash transaction worth approximately $270 million.
Neutral
PRNewsWire
21 days ago
Data from longest and largest hemophilia gene therapy study demonstrates sustained factor VIII expression and bleed control, with 81.3% of individuals remaining off prophylaxis No new safety signals observed SAN RAFAEL, Calif. , June 24, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced new data underscoring the long-term efficacy and safety of ROCTAVIAN ® (valoct...
Positive
The Motley Fool
about one month ago
It's been a wild ride for the stock market through the first five months of 2025. As of mid-February, Wall Street's major stock indexes could do no wrong, with the benchmark S&P 500 vaulting to an all-time record-closing high.
More Biomarin Pharmaceutical News

Company Profile

BioMarin Pharmaceutical, Inc. is a biotechnology company, which engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline include Vosoritide (BMN 111) for Achondroplasia and Valoctocogene Roxaparvovec (BMN 270) for Hemophilia A. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997 and is headquartered in San Rafael, CA.

Head office United States
CEO Alexander Hardy
Employees 3,040
Founded 1997
Website www.biomarin.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today